Skip to search formSkip to main contentSkip to account menu

volinanserin

Known as: (R)-(2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl)piperidin-4-yl)methanol, 4-piperidinemethanol, alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (alpha-R)-, alpha-(2,3-Dimethoxyphenyl)-1-(2-(4-fluorophenylethyl))-4-piperidine Methanol 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

FluorobenzenesPiperidinesSerotonin Antagonists

Narrower (1)

MDL 100907

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice
Prepulse inhibition of the startle reflex (PPI) is disrupted in several psychiatric disorders including schizophrenia… 
2018
2018
Synthesis and activity of functionalizable derivatives of the serotonin (5-HT) 5-HT2A receptor (5-HT2AR) antagonist M100907.
2018
2018
The Involvement of 5-HT 2A Receptor in the Regulation of Sleep and Wakefulness, and the Potential Therapeutic Use of Selective 5-HT 2A Receptor Antagonists and Inverse Agonists for the Treatment of…
Several agents have been shown to improve sleep induction and/or maintenance in patients with primary or comorbid insomnia. These… 
2018
2018
Serotonin Receptor Inverse Agonists or Antagonists for Use in Reducing Amyloid-Beta Peptides and Accumulation
Several approaches that are directed against amyloid plaque deposition, or against the formation of amyloid precursor protein… 
Review
2017
Review
2017
Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists Specifically Promote Slow Wave Sleep (Stage N3) in Man
Several drug classes are widely prescribed when difficulties with sleep induction or sleep maintenance occur, as is the case in… 
2016
2016
The 5-HT2A antagonist Volinanserin attenuates spontaneous nicotine withdrawal syndrome in rats
2014
2014
Development of novel chiral capillary electrophoresis methods for the serotonin receptor (5-HT2A) antagonist MDL 100,907 (volinanserin) and for its key intermediate compound.
Highly Cited
2008
Highly Cited
2008
5-HT(2A) inverse-agonists for the treatment of insomnia.
Nearly one half of the adult population in the U.S. experience some symptoms of insomnia (difficulties with getting to sleep… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)